Moderna Inc MRNA shares are trading lower by 2.4% to $113.80 Thursday afternoon. The stock has seen volatility in recent sessions amid rising COVID-19 cases in the U.S.
Rising COVID-19 cases might lead to increased demand for vaccines, including Moderna's. Governments and health organizations could emphasize the importance of vaccination, potentially driving higher sales of Moderna's vaccine doses.
Additionally, if booster shots are recommended to combat new variants or waning immunity, Moderna's stock could rise as it benefits from additional vaccine sales.
What Else?
Last week, during the first Republican primary debate, Florida Gov. Ron DeSantis proudly touted the way he handled the Covid-19 pandemic, claiming the Sunshine State "led the country out of lockdown, and we kept our state free and open."
Meanwhile, COVID-19 hospitalizations in Florida saw more than 1,870 new admissions in the week ending Aug. 12 — an increase of 11.6% from the prior week.
The situation reflects a larger trend across the country: More than 12,600 new admissions were recorded the week ending Aug. 12. That's an increase of 21.6% from the prior week, according to data from the U.S. Centers for Disease Control and Prevention...Read More
According to data from Benzinga Pro, Moderna has a 52-week high of $217.25 and a 52-week low of $95.02.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.